HLB Therapeutics is posting a rise of around 6% in after-hours trading. On the same day, HLB also surged more than 10% after hours, with attention also focused on disclosures related to China's Hengrui Pharma. As of the afternoon of the 30th, HLB Therapeutics was trading at 2,725 won, up 165 won from the previous trading day, a gain of 6.45%.

[HLB Surges in After-Hours Trading... Focus on Affiliate Share Price Movements]

As the share price shows an upward trend, the HLB Group's new drug development schedule has emerged as a key point of interest. In particular, it is notable that HLB jumped more than 10% in after-hours trading that day. With HLB's share price moving sharply even after the close of the regular session, attention is turning to the future share price movements of the group's affiliates.

[Liver Cancer Drug Development... Hengrui Pharma and FDA Review as Variables]

Regarding HLB's liver cancer drug development, the role of China's Hengrui Pharma is important. Amid HLB Therapeutics' 6% rise and HLB's after-hours surge, market attention is shifting to the FDA's follow-up review process.

[Points to Note When Investing]

However, it has not been confirmed whether HLB Therapeutics' share price rise directly stemmed from news related to Hengrui Pharma. It is also impossible to say at this point whether HLB's after-hours upward momentum will continue into the next trading day.

[This article is for investment reference purposes only and does not recommend the purchase or sale of any specific stock. Share prices may fluctuate depending on market conditions. This article was written with some assistance from AI.]